Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.
Why PAVmed Shares Are Falling Today
PAVmed Inc. (NASDAQ: PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures.
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
PAVmed Inc (NASDAQ:PAVM), its majority-owned subsidiaries Lucid Diagnostics Inc (NASDAQ:LUCD), and Veris Health Inc provided a strategic business update outlining near-term strategic priorities…
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $4.25 to $3.1.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $4.25
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $5 to $4.25.
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $5
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $7 to $5.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.